330.33
-0.90 (-0.27%)
| Penutupan Terdahulu | 331.23 |
| Buka | 331.76 |
| Jumlah Dagangan | 92,385 |
| Purata Dagangan (3B) | 404,483 |
| Modal Pasaran | 7,293,752,320 |
| Harga / Jualan (P/S) | 37.78 |
| Harga / Buku (P/B) | 9.36 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Keuntungan | -258.64% |
| Margin Operasi (TTM) | -64.84% |
| EPS Cair (TTM) | -21.92 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.85% |
| Nisbah Semasa (MRQ) | 6.10 |
| Aliran Tunai Operasi (OCF TTM) | -455.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -296.99 M |
| Pulangan Atas Aset (ROA TTM) | -36.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -80.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Madrigal Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.75 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.79% |
| % Dimiliki oleh Institusi | 105.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Paulson & Co. Inc. | 31 Dec 2024 | 2,042,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 460.00 (B. Riley Securities, 39.26%) | Beli |
| Median | 450.50 (36.38%) | |
| Rendah | 420.00 (Canaccord Genuity, 27.15%) | Beli |
| Purata | 445.25 (34.79%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 316.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 460.00 (39.25%) | Beli | 315.48 |
| Canaccord Genuity | 02 May 2025 | 420.00 (27.15%) | Beli | 315.48 |
| UBS | 02 May 2025 | 458.00 (38.65%) | Beli | 315.48 |
| JMP Securities | 24 Apr 2025 | 443.00 (34.11%) | Beli | 319.93 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |